Zepbound KwikPen Instructions for Use issued ahead of the device's US launch

Eli Lilly has issued a new FDA-approved Instructions for Use document for the Zepbound KwikPen, numbered ZEPKP-0002-IFU-20260121, ahead of the device's launch in the United States [Development summary]. The document changes how patients are told to handle the pen before each weekly injection, and it arrives alongside other recent updates to the drug's prescribing information ^[1].

The most notable change is that priming is now required before every weekly injection, not just the first time a patient uses a new pen [Development summary]. Patients are also told to check for a dose-window icon that must be visible before the needle is withdrawn from the skin, and they are explicitly instructed not to count clicks while dialing the dose [Development summary]. Lilly's full prescribing information confirms that administration instructions for the device were revised, listing "Dosage and Administration (2.4)" as a recent major change dated 01/2026 ^[1].

The prescribing information also states that pen needles are not included with the device [Development summary], meaning patients will need to obtain needles separately before their first dose.

This update comes as Lilly's label for Zepbound has seen several other changes on a similar timeline. The prescribing information lists a new warning, added in 01/2026, that a Zepbound KwikPen must never be shared between patients, even if the pen needle is changed ^[1]. Separately, the label notes that language on suicidal behavior and ideation was removed as of 02/2026, and that warnings about severe gastrointestinal adverse reactions were updated the same month ^[1]. A warning about diabetic retinopathy complications in patients with type 2 diabetes was added in 08/2026 ^[1].

Zepbound (tirzepatide) carries a boxed warning about thyroid C-cell tumors seen in rodent studies; it is not known whether the drug causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans, and the drug remains contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 ^[1]. The most common adverse reactions reported in at least 5% of patients in trials include nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, and gastroesophageal reflux disease ^[1].

Why it matters for patients

For people already on Zepbound or starting it, the KwikPen's instructions determine whether a weekly dose is delivered correctly. A priming step required before every injection is a change from a device where priming was needed only once, so patients switching from an older process or from a different device will need to relearn the routine described in the new Instructions for Use [Development summary]. The instruction to watch for a dose-window icon before withdrawing the needle, and not to rely on counting clicks, suggests Lilly wants patients using a visual confirmation rather than a tactile or auditory cue to know the full dose has been delivered [Development summary]. Because pen needles are not included with the KwikPen, patients will need to plan ahead to have compatible needles on hand before their first injection [Development summary]. None of the sources describe what happens if priming is skipped or if the dose window is not checked, so the practical consequences of missing these steps are not detailed here.

What happens next

The prescribing information shows a revision date of 8/2026, with several labeled changes taking effect across January, February, and August 2026, including the KwikPen administration update in January 2026 and the sharing warning also dated 01/2026 ^[1]. The sources do not specify an exact retail launch date for the KwikPen device itself beyond the instructions being issued ahead of its U.S. launch [Development summary].